or words of
similar meaning. Such statements are based on our current expectations and
certain assumptions, and are, therefore, subject to certain risks and
uncertainties. A variety of factors, many of which are beyond Siemens'
control, affect its operations, performance, business strategy and results
and could cause the actual results, performance or achievements of Siemens
worldwide to be materially different from any future results, performance
or achievements that may be expressed or implied by such forward-looking
statements. For us, particular uncertainties arise, among others, from:
changes in general economic and business conditions (including margin
developments in major business areas); the challenges of integrating major
acquisitions and implementing joint ventures and other significant
portfolio measures; changes in currency exchange rates and interest rates;
introduction of competing products or technologies by other companies; lack
of acceptance of new products or services by customers targeted by Siemens
worldwide; changes in business strategy; the outcome of pending
investigations and legal proceedings; our analysis of the potential impact
of such matters on our financial statements; as well as various other
factors. More detailed information about our risk factors is contained in
Siemens' filings with the SEC, which are available on the Siemens website,
http://www.siemens.com, and on the SEC's website,
http://www.sec.gov.
Should one or more of these risks or uncertainties materialize, or should
underlying assumptions prove incorrect, actual results may vary materially
from those described in the relevant forward-looking statement as expected,
anticipated, intended, planned, believed, sought, estimated or projected.
Siemens does not intend or assume any obligation to update or revise these
forward-looking statements in light of developments which differ
'/>"/>SOURCE Siemens Medical Solutions Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related biology technology :1.
Siemens health services president calls IT benefits unassailable2.
Medical College receives $377K to study brain disease3.
Lucigen receives $750K grant to boost biofuel yields4.
Medical College receives $1.4M cancer grant5.
Wisconsin biotech firm receives $107K NIH grant6.
InvivoSciences receives NIH grant for heart technology7.
Medical College receives $11 million grant to study high blood pressure8.
Madison business receives $115,000 of new state biofuels funding9.
Superior receives funds for technical training10.
UWM receives state funding for plastics research11.
GEs Centricity EHR receives federal certification